Start with the document
The source register.
These records serve different purposes. Open a source to find its original document and the articles that use it. A title, abstract, registry or label does not support every claim someone might attach to a medicine name.
CoreAge Rx: Semaglutide Microdosing Therapy
CoreAge Rx: shared microdose GLP-1 offer and footer terms
Provider offer and billing disclosures · Checked 2026-09-27
Read the original document ↗Used in this reading
Wegovy prescribing information, revised June 2026
Approved-product prescribing information · Checked 2026-09-27
Read the original document ↗Used in this reading
- CoreAge Rx semaglutide microdosing review: the claim, the offer and the unresolved details
- Semaglutide microdosing care compared: goals, evidence and quoted terms
- AgelessRx semaglutide microdosing review: a survey, a trial and a subscription
- Noom semaglutide microdosing review: program identity, price changes and reported outcomes
- What does semaglutide microdosing mean in an advertisement?
- Semaglutide and longevity claims: what the mortality evidence actually says
- Who was studied? Reading a semaglutide result beyond the headline
- Semaglutide salt forms and compounding: what the pharmacy record must clarify
FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Current regulatory safety information · Checked 2026-09-27
Read the original document ↗Used in this reading
- CoreAge Rx semaglutide microdosing review: the claim, the offer and the unresolved details
- Semaglutide microdosing care compared: goals, evidence and quoted terms
- AgelessRx semaglutide microdosing review: a survey, a trial and a subscription
- Noom semaglutide microdosing review: program identity, price changes and reported outcomes
- What does semaglutide microdosing mean in an advertisement?
- Semaglutide salt forms and compounding: what the pharmacy record must clarify
FDA: Understanding the Risks of Compounded Drugs
Regulatory explanation · Checked 2026-09-27
Read the original document ↗Used in this reading
- CoreAge Rx semaglutide microdosing review: the claim, the offer and the unresolved details
- Semaglutide microdosing care compared: goals, evidence and quoted terms
- AgelessRx semaglutide microdosing review: a survey, a trial and a subscription
- Semaglutide and longevity claims: what the mortality evidence actually says
- Semaglutide salt forms and compounding: what the pharmacy record must clarify
AgelessRx: Microdosing Semaglutide product, price and survey disclosures
Provider product and service description · Checked 2026-09-27
Read the original document ↗Used in this reading
AgelessRx: Microdosing GLP-1 for Longevity, trial update September 2, 2026
Sponsor research announcement, not published trial results · Checked 2026-09-27
Read the original document ↗Used in this reading
Noom: Microdose GLP-1Rx program and offer qualifications
Noom: current medication programs and pricing
Provider pricing and outcome footnotes · Checked 2026-09-27
Read the original document ↗Used in this reading
Noom: program cost article, updated September 22, 2026
Noom: microdosing GLP-1 article, updated September 3, 2026
Provider educational marketing and older price terms · Checked 2026-09-27
Read the original document ↗Used in this reading
FDA: Compounding and the FDA, Questions and Answers
FDA: Understanding Unapproved Use of Approved Drugs, Off Label
FDA: Locate a State-Licensed Online Pharmacy
Government pharmacy information · Checked 2026-09-27
Read the original document ↗Used in this reading
Lincoff and colleagues: SELECT cardiovascular outcomes trial, NEJM 2023
Primary randomized trial full text · Checked 2026-09-27
Read the original document ↗Used in this reading
Scirica and colleagues: SELECT mortality and COVID-19 analysis, JACC 2024, PubMed abstract
Primary trial analysis abstract · Checked 2026-09-27
Read the original document ↗Used in this reading
Wilding and colleagues: STEP 1 semaglutide weight-management trial, NEJM 2021, PubMed abstract
Primary randomized trial abstract · Checked 2026-09-27
Read the original document ↗Used in this reading
ClinicalTrials.gov: SELECT, NCT03574597
Primary clinical trial registry · Checked 2026-09-27
Read the original document ↗Used in this reading
ClinicalTrials.gov: STEP 1, NCT03548935
Primary clinical trial registry · Checked 2026-09-27
Read the original document ↗Used in this reading
Hims — weight-loss membership FAQ
Official membership renewal, product options, separate trial references, state-dependent assessment and variable response times; not an individual care or outcome record. · Checked 2026-09-29
Read the original document ↗Used in this reading
Hims — weight-loss membership and medication offer
Official clinical weight-care description, separate medication and membership charges, qualified trial footnotes and compensated-testimonial disclosure; oral-study timing differs from the FAQ. · Checked 2026-09-29
Read the original document ↗Used in this reading
Hims — canceling a weight-loss membership
Official distinction between membership and medication renewal; it does not establish a selected prepaid medicine refund. · Checked 2026-09-29
Read the original document ↗Used in this reading
Wegovy — prescribing information revised June 2026
Approved-product prescribing information for injection and tablets; indication, contraindication and warning context remains product-specific and does not validate marketed microdosing. · Checked 2026-09-29
Read the original document ↗Used in this reading
- Hims semaglutide review: which study sits behind the weight-loss headline?
- Ro semaglutide review: separate a medicine trial from a membership survey
- WeightWatchers Clinic semaglutide review: three kinds of outcome evidence
- Found semaglutide review: preventive microdosing claims need their own evidence
- Calibrate semaglutide review: a program result needs a consistent denominator
- Form Health semaglutide review: what an all-pathways average can establish
- PlushCare semaglutide review: a clinical assessment is not a microdosing promise
- LifeMD semaglutide review: a money-back promise is not an efficacy study
- Henry Meds semaglutide review: the microdose offer and its unresolved product record
Ro — Body weight-management membership
Official multi-medicine clinical offer, monthly versus annual-prepaid membership figures and qualified mixed-GLP-1 member survey; medication costs separate. · Checked 2026-09-29
Read the original document ↗Used in this reading
Wilding and colleagues — STEP 1, NEJM 2021, PubMed abstract
Primary randomized weight-management trial abstract and funding statement; defined semaglutide/placebo and lifestyle comparison, not a commercial microdose or longevity study. · Checked 2026-09-29
Read the original document ↗Used in this reading
- Ro semaglutide review: separate a medicine trial from a membership survey
- Calibrate semaglutide review: a program result needs a consistent denominator
- PlushCare semaglutide review: a clinical assessment is not a microdosing promise
- LifeMD semaglutide review: a money-back promise is not an efficacy study
Ro — Body membership insurance explanation
Official product-specific coverage pathways and distinct Medicare, TRICARE, FEHB and Medicaid conditions; coverage and personal eligibility are not guaranteed. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ro — returns and refunds
Official prescription-product final-sale policy and error-contact qualification; not a complete membership-refund agreement. · Checked 2026-09-29
Read the original document ↗Used in this reading
WeightWatchers Clinic — semaglutide care through Med+
Official clinical service, membership commitment and renewal terms, separate medicine costs and observational program comparison. · Checked 2026-09-29
Read the original document ↗Used in this reading
WeightWatchers Clinic — Wegovy pill and Med+ terms
Official product-specific offer with separate trial comparisons, sponsored mixed-medicine single-arm study description and qualified prepaid-medication cancellation terms. · Checked 2026-09-29
Read the original document ↗Used in this reading
Found — GLP-1 microdosing program
Official compounded-semaglutide offer and preventive-health marketing; the reviewed page does not establish matching controlled finished-product results for each proposed benefit. · Checked 2026-09-29
Read the original document ↗Used in this reading
FDA — concerns with unapproved GLP-1 drugs
Current regulatory explanation of unapproved products, salts, safety reports and compounding concerns; not provider-specific defect findings, incidence rates or individual legal clearance. · Checked 2026-09-29
Read the original document ↗Used in this reading
Found — clinical weight-management program
Official broader branded and compounded program, separate branded-trial claims, selected self-reported outcomes and paid member appearances; not microdose-specific efficacy evidence. · Checked 2026-09-29
Read the original document ↗Used in this reading
Found — terms and conditions
Official terms updated November 13, 2024, covering medical-group roles, subscription access, cancellation and geographic limits; personal plan terms remain unverified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Calibrate — medication policy
Official named medicine options and explicit no-compounded-GLP-1 policy; broad safety language and program outcomes are provider statements, not individual clinical conclusions. · Checked 2026-09-29
Read the original document ↗Used in this reading
Calibrate — program FAQ
Official clinical visit, coaching, commitment and cost details; individual and employer eligibility wording is mixed and outcome figures differ across pages. · Checked 2026-09-29
Read the original document ↗Used in this reading
Calibrate — Metabolic Reset overview
Official medication-plus-coaching program; its three-year outcome figure differs from the FAQ and is not semaglutide-only evidence. · Checked 2026-09-29
Read the original document ↗Used in this reading
Form Health — weight and cardiometabolic care
Official clinician-team model and program averages across treatment pathways, including care without medication; no isolated semaglutide effect established. · Checked 2026-09-29
Read the original document ↗Used in this reading
Form Health — Wegovy clinical care
Official conditional Wegovy prescribing and monitoring description; not a personal prescription, coverage decision or microdosing offer. · Checked 2026-09-29
Read the original document ↗Used in this reading
Form Health — program FAQ and access requirements
Official PCP relationship, recent visit and records requirements, monthly clinician/dietitian care, self-pay exclusions and qualified cancellation discussion. · Checked 2026-09-29
Read the original document ↗Used in this reading
Form Health — Wegovy pill FAQ
Official product education and no-compounded-medication statement; internal launch-year discrepancy and cross-formulation claims do not replace the current product label. · Checked 2026-09-29
Read the original document ↗Used in this reading
PlushCare — medical weight-loss care
Official physician-led assessment, conditional medication options, treatment exclusions and separate visit, membership, medicine and laboratory costs; no verified microdosing program. · Checked 2026-09-29
Read the original document ↗Used in this reading
FDA — unapproved use of approved drugs
Regulatory explanation of off-label use of an approved product; it does not confer approval on a finished compound. · Checked 2026-09-29
Read the original document ↗Used in this reading
LifeMD — weight-management program
Official conditional branded-medicine care, separate fees, paid testimonials and program-specific government-coverage exclusion; not a complete selected agreement or semaglutide-only outcome study. · Checked 2026-09-29
Read the original document ↗Used in this reading
LifeMD — weight-management refund guidelines
Official policy updated May 9, 2025; qualifying continuous enrollment, participation requirements, deductions and request window limit the outcome-linked subscription refund. · Checked 2026-09-29
Read the original document ↗Used in this reading
Henry Meds — GLP-1 microdose offer
Official compounded-semaglutide offer, conditional evaluation and age scope; proposed gentleness and weight effects are not independently demonstrated finished-product outcomes. · Checked 2026-09-29
Read the original document ↗Used in this reading
Henry Meds — program schedule
Official schedule dated December 3, 2025; program intervals differ from the dedicated microdose page and an oral heading/ingredient mismatch remains unresolved. · Checked 2026-09-29
Read the original document ↗Used in this reading
Henry Meds — terms of service
Official platform, clinician and pharmacy roles; location, self-pay, subscription, cancellation and limited-refund conditions. No personal agreement or pharmacy compliance determination. · Checked 2026-09-29
Read the original document ↗Used in this reading
Mochi Health: weight-management service and offer
Official video-assessment, compounded menu and membership price statements; medicine and diagnostics separate, selected product and microdosing program unverified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Mochi Health: program and medicine FAQ
Provider-reported member average lacks the denominator, timeframe and comparator in the reviewed passage; starting medicine price varies with the prescription and is not a selected quote. · Checked 2026-09-29
Read the original document ↗Used in this reading
FDA: concerns about unapproved GLP-1 drugs
Primary explanation of unapproved finished products and semaglutide salt distinctions; no individual pharmacy legality audit or administration instructions. · Checked 2026-09-29
Read the original document ↗Used in this reading
Mochi Health: standard and Wellness Plus arrangements
Official distinction between membership programs; observed promotional and medicine-price language differs from the service/FAQ, with no selected quote or personal coverage verified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Mochi Health: promotion terms
New-member promotion excludes medication and Wellness Plus; does not establish that separate promotions or plans can be combined. · Checked 2026-09-29
Read the original document ↗Used in this reading
Mochi Health: membership and medication terms
Selected cancellation and refund clauses from the official terms; account/phone method, term-end cancellation and pharmacy-stage medicine restriction retained. Full document not claimed read. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ivim Health: clinical-service pathway
Official provider assessment and conditional pharmacy description; no personal prescription or selected preparation verified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ivim Health: program, membership and research descriptions
Provider identifies retrospective observational mixed semaglutide/tirzepatide and branded/compounded research; no randomized program comparison or independent original-paper analysis claimed. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ivim Health: GLP-1 ID offer
Official compounded-program starting price and commitment descriptions; external trial comparison is not head-to-head randomization. No administration details reproduced. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ivim Health: membership agreement
Official selected-term obligation and48-hour nonrenewal notice; does not resolve separate program-page cancellation wording. · Checked 2026-09-29
Read the original document ↗Used in this reading
Ivim Health: selected program and refund terms
Selected section16 and GLP-1 ID clinical/payment passages read; unshipped-refund deductions and medically-ineligible waiver retained. No complete legal-document review or personal refund decision claimed. · Checked 2026-09-29
Read the original document ↗Used in this reading
RemedyMeds: program and microdose marketing
Official actual clinical program with explicit microdose marketing; mixed self-reported program outcomes and testimonials are not an exact microdose efficacy study. · Checked 2026-09-29
Read the original document ↗Used in this reading
RemedyMeds: selected membership, payment and warranty terms
Selected first27,300 characters of official terms read. Twelve-month warranty excludes microdosing and branded products; cash payment, advance billing, renewal and eligibility clauses retained. Not full-document legal review. · Checked 2026-09-29
Read the original document ↗Used in this reading
RemedyMeds: separate compounded-semaglutide offer
Initial and recurring four-week supply price belongs to this product page, not a verified selected microdose quote; payment and warranty wording differs from broader terms. · Checked 2026-09-29
Read the original document ↗Used in this reading
FDA: off-label use of approved drugs
Primary distinction between an approved drug’s unapproved use and an unapproved finished product; no personal treatment or legal-clearance recommendation. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amble: clinical program, survey and pricing
Official physician-review service; May2025 compensated member self-reports span mixed treatments, not a semaglutide-only randomized study. Prepaid price tables differ. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amble: refund policy
Official one-time versus automatic-renewal wording and prescription-stage refund conditions; consultation and medicine restrictions do not establish an individual refund. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amble: selected extended-membership terms
Selected extended-plan and medically-inappropriate-treatment refund clauses;15-day renewal notice retained. No full legal review or reconciliation of conflicting refund wording claimed. · Checked 2026-09-29
Read the original document ↗Used in this reading
Eden: clinical service and outcome claims
Official independent-provider/pharmacy roles;111-member six-month self-report is separate from the approved-Wegovy research statement and is not semaglutide-specific efficacy proof. · Checked 2026-09-29
Read the original document ↗Used in this reading
STEP1: randomized semaglutide trial abstract
Primary PubMed abstract only:1,961 adults without diabetes,68-week placebo/lifestyle comparison; Novo Nordisk funding. Not an Eden compound trial or independent full-paper analysis. · Checked 2026-09-29
Read the original document ↗Used in this reading
Eden: January5,2026 program article
Dated program-pricing article; selected first15,000 characters read, and the old advertised price is not verified as the current selected September quote. · Checked 2026-09-29
Read the original document ↗Used in this reading
Eden: selected eligibility, payment and guarantee terms
Selected age/location, cash-pay/no-reimbursement, renewal and six-month guarantee provisions; form exclusions and verification conditions retained, not a complete legal review or efficacy proof. · Checked 2026-09-29
Read the original document ↗Used in this reading
Eden: refund policy
Official unavailable-treatment exception for unshipped portions and thirty-day approved processing; not a universal cancellation refund. · Checked 2026-09-29
Read the original document ↗Used in this reading
Fridays: one-month compounded microdose offer
Explicit microdose marketing and279 one-month offer;96.8% statistic is paid-order fulfillment/delivery, not clinical efficacy. Oral/nasal labels do not verify a selected form. · Checked 2026-09-29
Read the original document ↗Used in this reading
Fridays: three-month compounded microdose subscription
Separate596 total three-month offer with described inclusions; not a selected individual quote or evidence that another promotion applies. · Checked 2026-09-29
Read the original document ↗Used in this reading
Fridays: wider program pricing
Separate Wegovy membership promotion and annual-plan equivalent excludes medicine; not the price of the compounded microdose offer. · Checked 2026-09-29
Read the original document ↗Used in this reading
Fridays: selected program terms
Selected age/location,72-hour cancellation and limited refund provisions read; no personal eligibility or full-document legal determination. · Checked 2026-09-29
Read the original document ↗Used in this reading
Sesame: Success service, prices and billing FAQ
Official service and billing page: care-only prices, commitments,28-day billing wording, laboratory exceptions and first-visit refunds. Study illustrations are not measured subscriber outcomes; selected reading excludes testimonial portions. · Checked 2026-09-29
Read the original document ↗Used in this reading
Sesame: selected general service terms
Federal-program nonbeneficiary certification including Medicare/Medicaid/TRICARE; separate Membership Services discount product is not assumed to share Success terms. Selected clauses only. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amazon One Medical: weight-management primary care
Official assessment, nutrition/exercise, conditional prescription and referral scope; no selected semaglutide formulation or microdose program verified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amazon One Medical: October27,2025 GLP-1 education
Dated article contains an outdated pill-availability statement; current June2026 Wegovy label controls the approved-form correction, not the provider’s current catalog. · Checked 2026-09-29
Read the original document ↗Used in this reading
Wegovy: June2026 US prescribing information
Selected current highlights, indications, contraindications and warning ranges read from the complete label; injection/tablet indications are product-specific. No entire-label reading, provider-supply verification or administration advice claimed. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amazon One Medical: membership and scheduled visits
Standard199 annual continuing membership is separate from scheduled visit billing and medicine costs; not the distinct On-Demand ED program. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amazon One Medical: membership and practice access
Official Prime99 annual membership and distinction between nationwide quick app care and scheduled visits in practice states; no universal weight-care availability inferred. · Checked 2026-09-29
Read the original document ↗Used in this reading
Amazon One Medical: insurance and Seniors practices
Original Medicare and selected Medicare Advantage participation is practice/plan-specific; not personal coverage confirmation or a claim about all One Medical products. · Checked 2026-09-29
Read the original document ↗Used in this reading
DrHouse: physician weight-management care
Official conditional clinical service, medicine examples and limited delivery geography. Older oral-GLP-1 exclusivity wording is corrected against current label, not adopted as current fact. · Checked 2026-09-29
Read the original document ↗Used in this reading
DrHouse: GLP-1 clinical FAQ
Official named medicine examples and conditional clinical/laboratory review; different ingredients are not collapsed into semaglutide and no personal eligibility or dosing directions supplied. · Checked 2026-09-29
Read the original document ↗Used in this reading
SELECT: cardiovascular-outcomes trial abstract and opening methods
Selected abstract and beginning methods only:17,604 adults with established cardiovascular disease and overweight/obesity without diabetes; Novo Nordisk funding. No full-paper or mortality-substudy analysis claimed. · Checked 2026-09-29
Read the original document ↗Used in this reading
DrHouse: visit price and insurance FAQ
129 self-pay consultation or covered copay, possible additional follow-up charges; Medicare participation and Medicaid exclusion do not establish medicine coverage. · Checked 2026-09-29
Read the original document ↗Used in this reading
DrHouse: refund FAQ
Completed guidance/referral or other care may preclude a refund without a prescription; approved refunds typically take5–10business days, not guaranteed approval. · Checked 2026-09-29
Read the original document ↗Used in this reading
Get Medical Weight Management Care | Cleveland Clinic
Official clinical weight-management service describing assessment, conditional obesity medicine use and follow-up. Multiple locations are mentioned; no microdosing offer or individual prescription is established. · Checked 2026-09-29
Read the original document ↗Used in this reading
Obesity and Medical Weight Loss Center | Cleveland Clinic
Official Obesity and Medical Weight Loss Center description of interdisciplinary care and shared appointments. Program features are not product-specific clinical outcomes. · Checked 2026-09-29
Read the original document ↗Used in this reading
Obesity - Care at Mayo Clinic - Mayo Clinic
Official Mayo obesity-care access information, dated December 2, 2025. Referral exceptions, insurer requirements and medical-need prioritization remain; clinical treatment scope is supported separately by the Jacksonville record. · Checked 2026-09-29
Read the original document ↗Used in this reading
Bariatric Center in Jacksonville - Your first appointment
Official first-appointment description for the Bariatric Center in Jacksonville, dated November 18, 2025. Medicine examples and follow-up are conditional, not a guarantee across all Mayo locations or a microdosing offer. · Checked 2026-09-29
Read the original document ↗Used in this reading
Medical Weight Loss
Official medical weight-loss service describing nutrition, behavioral and other clinical support. No particular semaglutide preparation, microdosing program or drug-specific outcome is verified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Duke Lifestyle and Weight Management Center
Official Durham Lifestyle and Weight Management Center description of consultation and ongoing management. Insurance participation does not establish personal coverage or a treatment result. · Checked 2026-09-29
Read the original document ↗Used in this reading
The Northwestern Medicine Complex Weight Management Clinic
Official adult Complex Weight Management Clinic description. Adult overweight/obesity care is documented, not a named medicine offer or a guarantee of eligibility. · Checked 2026-09-29
Read the original document ↗Used in this reading
Nonsurgical Weight Loss Services in the Western Suburbs
Official Western Suburbs nonsurgical program description of physician/dietitian assessment, structured support and possible medicines. Its separate program and population boundaries remain; no microdosing product is identified. · Checked 2026-09-29
Read the original document ↗Used in this reading
Medical Weight Management Program Overview
Official Medical Weight Management Program overview centered on clinical nutrition and medical assessment. Medicine-history review does not establish GLP-1 prescribing; visit frequencies can change and older remote-class wording does not confirm current access. · Checked 2026-09-29
Read the original document ↗Used in this reading
Weight Maintenance Program
Official weight-maintenance service describing dietitian meetings and group support. General references to research are not a separately reviewed primary trial or a verified medicine outcome. · Checked 2026-09-29
Read the original document ↗Used in this reading
Medical Weight Loss Treatment
Official medical weight-loss treatment description with evaluation and conditional GLP-1 care. The separate online second-opinion service does not establish ongoing treatment or a microdosing offer. · Checked 2026-09-29
Read the original document ↗Used in this reading
Weight Management Program
Official Weight Management Program record describing treatment families, ongoing support and conditional primary-care coordination. Virtual and insurance statements do not determine individual eligibility, coverage or exact medicine selection. · Checked 2026-09-29
Read the original document ↗Used in this reading
Weight Management Program
Official clinical weight-management program across New York City and Long Island. Adult and adolescent pathways remain distinct; accreditation and program breadth do not establish drug-specific outcomes. · Checked 2026-09-29
Read the original document ↗Used in this reading
Medication for Obesity
Official obesity-medication discussion naming different active medicines and describing supervision. Named examples are not a guaranteed prescription, current inventory or microdosing service. · Checked 2026-09-29
Read the original document ↗Used in this reading
Metabolic Health & Weight Loss Program | Yale Medicine
Official Metabolic Health & Weight Loss Program description of supervised nonsurgical care. Medicine examples are not a verified exhaustive current formulary or semaglutide microdosing offer. · Checked 2026-09-29
Read the original document ↗Used in this reading
Center for Weight Management | Yale Medicine
Official multidisciplinary weight-management center description. The page retains a planned 2022 move; current location, staffing, completed relocation and personal telehealth access are not established by that wording. · Checked 2026-09-29
Read the original document ↗Used in this reading
Johns Hopkins Medicine — Weight Management
Official indexed Weight Management page viewed September 29, 2026, reporting a same-day crawl after direct access was unavailable. Current origin content and appointment availability are unconfirmed; the curriculum reference is a provider attribution, not an independently reviewed Look AHEAD trial. · Checked 2026-09-29
Read the original document ↗Used in this reading
Johns Hopkins Medicine — Healthful Eating, Activity & Weight Program
Official indexed Healthful Eating, Activity & Weight Program page viewed September 29, 2026, reporting a same-day crawl. Direct-origin freshness is unverified; conditional medication management does not identify a microdosing product or personal prescription. · Checked 2026-09-29
Read the original document ↗Used in this reading
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA explanation of unapproved GLP-1 products, compounding concerns and different semaglutide salt identities. It is general regulatory context, not individual pharmacy clearance; adverse-event reports are not causal incidence estimates. · Checked 2026-09-29
Read the original document ↗Used in this reading
- Cleveland Clinic weight-management evidence review: clinical goals before longevity claims
- Duke Health weight-management evidence review: a whole program is not a drug trial
- Johns Hopkins weight-management evidence review: lifestyle care is not a semaglutide result
- Northwestern Medicine weight-management evidence review: keep the program and population together
- UCLA Health weight-management evidence review: nutrition care does not establish a GLP-1 offer
- NYU Langone weight-management evidence review: different medicines require different comparisons
Understanding Unapproved Use of Approved Drugs "Off Label"
FDA explanation of unapproved uses of approved drugs. Approval for one use does not establish safety and effectiveness for another, and off-label use is distinct from an unapproved compounded preparation. · Checked 2026-09-29
Read the original document ↗Used in this reading
Wegovy PI
Manufacturer-hosted prescribing information revised June 2026. Selected boxed-warning, indication, contraindication and warning sections reviewed; injection and tablet indications differ. No microdosing or healthy-person longevity indication is listed in the reviewed indications. · Checked 2026-09-29
Read the original document ↗Used in this reading
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Original randomized placebo-controlled SELECT report, funded by Novo Nordisk. Adults with established cardiovascular disease and overweight/obesity, without diabetes; cardiovascular primary outcome and secondary-testing hierarchy retained. Selected report sections reviewed, not the full appendix or protocol. · Checked 2026-09-29
Read the original document ↗Used in this reading
- Cleveland Clinic weight-management evidence review: clinical goals before longevity claims
- Johns Hopkins weight-management evidence review: lifestyle care is not a semaglutide result
- Stanford weight-management evidence review: GLP-1 care still needs an exact treatment identity
- NYU Langone weight-management evidence review: different medicines require different comparisons
- Yale Medicine weight-management evidence review: broad care claims need narrower outcome questions
Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed
Primary STEP 1 trial abstract on PubMed, funded by Novo Nordisk. Adults without diabetes, specified weight-related entry criteria, semaglutide versus placebo with lifestyle support over 68 weeks. Abstract and returned page reviewed, not the full paper or appendix. · Checked 2026-09-29
Read the original document ↗Used in this reading
- Mayo Clinic weight-management evidence review: a Jacksonville visit is not a microdosing promise
- Duke Health weight-management evidence review: a whole program is not a drug trial
- Northwestern Medicine weight-management evidence review: keep the program and population together
- UCLA Health weight-management evidence review: nutrition care does not establish a GLP-1 offer
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial - PubMed
Primary PubMed abstract and disclosures for the SELECT mortality analysis. This uses the same cardiovascular-disease cohort, not a new healthy-person microdosing trial; the full JACC paper was not reviewed. · Checked 2026-09-29
Read the original document ↗Used in this reading
SuperHealthy Rx: official microsema offer
Likeness Rx — GLP-1 weight care
CoreAge Rx: advertised shipping and support
SuperHealthy Rx: advertised shipping and support
Affirm: eligibility and payment-plan terms
IRS: eligible medical expenses for HSA and FSA payments
Federal expense-eligibility guidance · Checked 2026-10-10
Read the original document ↗